GLP-1+GIP 20 mg

GLP-1+GIP 20 mg vial – product information

GLP-1+GIP 20 mg is a synthetic peptide compound for research applications, designed to analyse complex metabolic pathways involved in incretin signalling and regulation of glucose metabolism. From a chemical perspective, the molecule is identified in the literature as tirzepatyd, a 39-amino-acid acylated peptide with a dual receptor profile towards GIP and GLP-1. The presence of the lipid modification promotes increased binding to plasma albumin, which under experimental conditions translates into increased structural stability and prolonged retention of the active biological form. Thus, GLP-1+GIP 20 mg can be described as a stable research reagent for laboratory analyses requiring prolonged biological exposure.

In the scientific literature, tirzepatyd 20 mg is described primarily in relation to the simultaneous activation of GIP and GLP-1 receptors. In research settings, activation of these receptors is observed to be associated with glucose-dependent insulin signalling, modulation of glucagon secretion and effects on incretin pathways related to energy metabolism. This receptor profile distinguishes GLP-1+GIP 20 mg from compounds targeting only a single incretin receptor and underpins its relevance in metabolic and endocrinological research.

See also GLP-1 GIP reagent 20mg in the device

GLP-1+GIP 20 mg - study profile

The effects of tirzepatyd 20 mg on gastrointestinal motility, central satiety mechanisms and changes in selected metabolic parameters also remain an important area of interest. In clinical studies and metabolic analyses of the molecule chemically identified as tirzepatyd, changes related to glucose metabolism, insulin sensitivity and energy balance have been observed; however, in the description of a laboratory product, this information is safest captured as literature data and lines of research rather than the claimed effect of the product. Randomised controlled trials have also evaluated the long-term sequelae of exposure to this molecule in different study designs, increasing its importance as a tool for analyses of long-term metabolic processes.

From a laboratory characterisation perspective, the main research advantages of GLP-1+GIP 20 mg include a well-described peptide structure, stability due to acylation and the ability to analyse two key incretin pathways simultaneously: GLP-1 and GIP. In the technical documentation and scientific literature, the molecule is referred to as tirzepatyd, while in the laboratory product description it can safely be presented as GLP-1+GIP 20 mg reagent vial, intended for research, comparative and reference analyses only.

Source:
The product is intended for scientific research and laboratory analysis. All articles and information on this website are for informational and educational purposes only.